Henry Schein (HSIC) is a Top-Ranked Growth Stock: Should You Buy?

Zacks identifies Henry Schein (HSIC), a global healthcare products and services distributor, as a notable growth prospect. Despite a #3 (Hold) Zacks Rank, HSIC boasts a strong 'A' VGM Score and a 'B' Growth Style Score. Analysts have recently raised fiscal 2025 earnings estimates to $4.86 per share, projecting 2.5% year-over-year growth and an average earnings surprise of 2.4%, suggesting HSIC merits consideration for growth-focused investors.

Analysis

Henry Schein (HSIC) presents a notable divergence between its neutral top-line rating and its underlying fundamental metrics, according to the Zacks rating system. While the stock carries a #3 (Hold) Zacks Rank, it is distinguished by a strong 'A' VGM Score and a favorable 'B' Growth Style Score. This suggests that despite a neutral overall outlook, the company exhibits strong characteristics for growth-focused investors. The forward-looking indicators are moderately positive; analysts forecast a 2.5% year-over-year earnings growth for the current fiscal year and have been revising estimates upward for fiscal 2025. Specifically, five analysts have increased their fiscal 2025 earnings estimates in the last 60 days, lifting the consensus to $4.86 per share. Furthermore, HSIC has a track record of consistently, if modestly, exceeding expectations, demonstrated by an average earnings surprise of 2.4%.

Key Decisions for Investors

• Investors should recognize the conflicting signals of a neutral Zacks #3 (Hold) rank against strong underlying 'A' VGM and 'B' Growth scores, warranting a deeper look into the specific drivers of each rating.
• Given the positive analyst revisions for fiscal 2025, portfolio managers should monitor upcoming earnings releases for confirmation that the projected earnings acceleration is materializing, as current-year growth is forecasted at a modest 2.5%.
• Growth-oriented investors may consider HSIC a candidate for their watchlist due to the favorable growth indicators, while the 'Hold' rating suggests that more cautious investors might wait for a clearer catalyst or an upgrade in the primary Zacks Rank before committing capital.